Therapeutic potential of monteplase in acute myocardial infarction as a powerful thrombolytic agent for pretreatment of coronary intervention

Cardiovascular Drug Reviews

Volumn 22, Issue 4, 2004, Pages 320-333

  Inoue, Teruo ^a   Nishiki, Ryoichi ^b   Kageyama, Manabu ^b   Node, Koichi ^a  

^a SAGA UNIVERSITY   (Japan)

^b EISAI CO LTD   (Japan)

Author keywords

Angioplasty; MI; Monteplase; PCI; Plasminogen activation; Thrombolysis

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; LANOTEPLASE; MONTEPLASE; MUTANT TISSUE TYPE PLASMINOGEN ACTIVATOR; STREPTOKINASE; TENECTEPLASE; TISSUE PLASMINOGEN ACTIVATOR; TISSUE PLASMINOGEN ACTIVATOR DERIVATIVE; UNCLASSIFIED DRUG; UROKINASE;

ACUTE HEART INFARCTION; ADULT; ANGIOCARDIOGRAPHY; AREA UNDER THE CURVE; BLOOD CLOT LYSIS; BOLUS INJECTION; BRAIN HEMORRHAGE; CLINICAL TRIAL; COMMUNITY HOSPITAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; GASTROINTESTINAL HEMORRHAGE; GINGIVA BLEEDING; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

EID: 12244258702     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2004.tb00149.x     Document Type: Review

References (31)

1. Barbash GI, Hod H, Roth A, et al. Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct artery after thrombolytic therapy in acute myocardial infarction. Am J Cardiol 1989;64:1231-1235.
2. Fujii S, Abendschein DR, Sobel BE. Augmentation of plasminogen activator inhibitor type 1 activity in plasma by thrombosis and by thrombolysis. J Am Coll Cardiol 1991;18:1547-1554.
3. Genser N, Lechleitner P, Maier J, et al. Rebound increase of plasminogen activator inhibitor type I after cessation of thrombolytic treatment for acute myocardial infarction is independent of type of plasminogen activator used. Clin Chem 1998;44:209-214.
4. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397-402.
5. Hamsten A, Wiman B, de Faire U, et al. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985;313:1557-1563.
6. Inoue T, Sakuma M, Yaguchi I, et al. Early recanalization and plasma brain natriuretic peptide as an indicator of left ventricular function after acute myocardial infarction. Am Heart J 2002;143:790-796.
7. Inoue T, Yaguchi I, Takayanagi K, et al. A new thrombolytic agent, monteplase, is independent of the plasminogen activator inhibitor in patients with acute myocardial infarction: Initial results of the Combining Monteplase with Angioplasty (COMA) trial. Am Heart J 2002;144:E5.
8. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin or both or neither among 17, 187 cases of suspected acute myocardial infarction. ISIS-2. Lancet 1988;2:349-360.
9. Julian-Vague I, Alessi MC, Joly P, et al. Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma insulin and acute-phase response. Arteriosclerosis 1989;9:362-367.
10. Kawai C, Hosoda S, Kimata S, et al. Coronary thrombolysis in acute myocardial infarction of E6010 (novel modified t-PA): A multicenter, double-blind dose-finding study (in Japanese). Jpn Pharmacol Ther 1994;22:3925-3950.
11. Kawai C, Yui Y, Hosoda S, et al. A prospective, randomized, double-blind multicenter trial of a single bolus injection of the novel modified t-PA E6010 in the treatment of acute myocardial infarction: Comparison with native t-PA. E6010 Study Group. J Am Coll Cardiol 1997;29:1447-1453.
12. Kimura K, Tsukahara K, Usui T, et al. Low-dose tissue plasminogen activator followed by planned rescue angioplasty reduces time to reperfusion for acute myocardial infarction treated at community hospitals. Jpn Circ J 2001;65:901-906.
13. Munkvad S, Gram J, Jesperson J. Increased of tissue-type plasminogen activator inhibitor type-1 (PAI-1) in plasma after thrombolytic therapy of patients with myocardial infarction: A randomized, placebo-controlled study. Fibrinolysis 1992;6:45-50.
14. Ohnishi A, Takazawa K, Fujita M, et al. Phase I study of the modified tissue plasminogen activator E6010 (in Japanese). Jpn J Clin Pharmacol Ther 1994;25:551-562.
15. O'Neill WW, Weintraub R, Grines CL, et al. A prospective, placebo-controlled, randomized trial of intravenous streptokinase and angioplasty versus lone angioplasty therapy of acute myocardial infarction. Circulation 1992;86:1710-1717.
16. 2-plasmin inhibitor complex to plasminogen activator inhibitor-1 reflects the fibrinolytic potential in plasma. Fibrinolysis Proteol 2000;14(Suppl 1):72.
17. Polonski L, Gasior M, Wasilewski J, et al. Outcomes of primary coronary angioplasty and angioplasty after initial thrombolysis in the treatment of 374 consecutive patients with acute myocardial infarction. Am Heart J 2003;145:855-861.
18. Ross AM, Coyne KS, Reiner JS, et al. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: The PACT trial. PACT investigators. Plasminogen-activator Angioplasty Compatibility Trial. J Am Coll Cardiol 1999;34:1954-1962.
19. Sane DC, Stump DC, Topol EJ, et al. Correlation between baseline plasminogen activator inhibitor levels and clinical outcome during therapy with tissue plasminogen activator for acute myocardial infarction. Thromb Haemost 1991;65:275-279.
20. Seifried E, Tanswell P, Rijken DC, Barrett-Bergshoeff MM, Su CA, Kluft C. Pharmacokinetics of antigen and activity of recombinant tissue-type plasminogen activator after infusion in healthy volunteers. Arzueimittelforschung 1988;38:418-422.
21. Simoons ML, Arnold AE, Betriu A, et al. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: No additional benefit from immediate percutaneous coronary angioplasty. Lancet 1988;1:197-203.
22. Spinler SA, Inverso SM. Update on strategies to improve thrombolysis for acute myocardial infarction. Pharmacotherapy 2001;21:691-716.
23. Suzuki S, Saito M, Suzuki N, et al. Thrombolytic properties of novel modified human tissue-type plasminogen activator (E6010): A bolus injection of E6010 has equivalent potency of lysing young and aged canine coronary thrombi. J Cardiovasc Pharmacol 1991;17:738-746
24. The TIMI Research Group. Immediate vs. delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction. TIMI II A results. JAMA 1988;260:2849-2858.
25. Topol EJ, Califf RM, George BS, et al. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1987;317:581-588.
26. Uto K, Ota Y, Mizuno M, et al. Impact of intravenous thrombolysis prior to percutaneous coronary intervention in reperfusion therapy for acute myocardial infarction (in Japanese). J Cardiol 2002;40:241-248.
27. van Meijer M, Smilde A, Tans G, et al. The suicide substrate reaction between plasminogen activator inhibitor 1 and thrombin is regulated by the cofactors vitronectin and heparin. Blood 1997;90:1874-1882.
28. White HD, Norris RM, Brown MA, et al. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med 1987;317:850-855.
29. Widimsky P, Groch L, Zelizko M, et al. Multicentre randomized trial comparing transport to primary angioplasty vs. immediate thrombolysis vs. combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. The PRAGUE study. Eur Heart J 2000;21:823-831.
30. Yaguchi I, Inoue T, Nishiki R et al. Injection of monteplase prior to percutaneous coronary intervention maintains left ventricular function and prevents left ventricular remodeling in acute myocardial infarction combining monteplase with angioplasty: COMA trial. J Am Coll Cardiol 2003;41(Suppl A):387A-388A (abstract).
31. Zijlstra F, de Boer MJ, Hoorntje JC, et al. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993;328:680-684.